Balyasny Asset Management
IPSC icon

Balyasny Asset Management’s Century Therapeutics IPSC Stock Holding History

Balyasny Asset Management’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.5M Buy
5,522,944
+505,211
+10% +$1.15M 0.02% 923
2026
Q1 		$11.3M Buy
+5,017,733
New +$10.6M 0.01% 979

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Balyasny Asset Management's IPSC Position: Q2 2026 in Review

Balyasny Asset Management increased its Century Therapeutics (IPSC) stake by 10% in Q2 2026, buying an estimated $1.15M and bringing the position to 5,522,944 shares worth $13.5M. The position accounts for 0.02% of the portfolio, ranked #923.

Balyasny Asset Management first reported a position in IPSC in Q1 2026 and has held it in 2 quarters since. 99 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

  • Balyasny Asset Management held 5,522,944 shares of Century Therapeutics worth $13.5M as of Q2 2026.
  • Balyasny Asset Management bought 505,211 Century Therapeutics shares in Q2 2026, an estimated $1.15M.
  • Century Therapeutics made up 0.02% of Balyasny Asset Management's portfolio in Q2 2026, its #923 holding.
  • Balyasny Asset Management first reported a position in Century Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 99 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.